Pf-06462700 (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
60 | Aplastic anemia | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04350606 (ClinicalTrials.gov) | July 25, 2020 | 1/4/2020 | A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia | A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF PF-06462700 ADMINISTERED INTRAVENOUSLY AT 40 MG/KG/DAY FOR 4 DAYS IN JAPANESE PARTICIPANTS WITH MODERATE AND ABOVE APLASTIC ANEMIA | Aplastic Anemia | Biological: PF-06462700 | Pfizer | NULL | Recruiting | 2 Years | N/A | All | 3 | Phase 3 | Japan |